>such a financial arrangement could be very positive... call it a partnership or whatever.<
Even with a plentiful cash infusion from a (hypothetical) finance-only partner, GTC would probably still need a separate partner for ATryn development/commercialization.
Exception: if a finance-only partner were uncommonly accommodating, GTC might be able to manage a full-fledged development program in-house for multiple ATryn indications and also do the selling for the HD indication, deferring a commercialization partnership until one or more non-HD indications were closer to fruition. But this runs contrary to what GTC has publicly stated about its intentions for the ATryn program(s).
Market Data 
Markets 
AI
